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Experimental data and few clinical non-randomized studies have shown that inhibition of the renin-angiotensin system by
angiotensin-converting enzyme (ACE) associated or not with the use of mycophenolate mofetil (MMF) could delay or even halt
the progression of chronic allograft nephropathy (CAN). In this retrospective historical study, we investigated whether ACE
inhibition (ACEI) associated or not with the use of MMF has the same effect in humans as in experimental studies and what
factors are associated with a clinical response. A total of 160 transplant patients with biopsy-proven CAN were enrolled. Eighty-
one of them were on ACE therapy (G1) and 80 on ACEI–free therapy (G2). Patients were further stratified for the use of MMF. G1
patients showed a marked decrease in proteinuria and stabilized serum creatinine with time. Five-year graft survival after CAN
diagnosis was more frequent in G1 (86.9 vs 67.7%; P < 0.05). In patients on ACEI-free therapy, the use of MMF was associated
with better graft survival. The use of ACEI therapy protected 79% of the patients against graft loss (OR = 0.079, 95%CI = 0.015-
0.426; P = 0.003). ACEI and MMF or the use of MMF alone after CAN diagnosis conferred protection against graft loss. This
finding is well correlated with experimental studies in which ACEI and MMF interrupt the progression of chronic allograft
dysfunction and injury. The use of ACEI alone or in combination with MMF significantly reduced proteinuria and stabilized serum
creatinine, consequently improving renal allograft survival.
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Introduction
Chronic allograft nephropathy (CAN) is present in 40-
60% of allograft biopsies 24 months after transplantation
and is the most common cause of late renal graft failure
(1,2). CAN is characterized by progressive deterioration of
renal function produced by sclerotic changes affecting
blood vessels, glomeruli, interstitium, and tubules and is
graded according to the degree of damage to the last two
parameters (3). Even though the functional and morpho-
logic findings of CAN have been well characterized, the
progressive mechanisms leading to deterioration of graft
function are poorly understood (4). Apart from the classical
immune events, many other risk factors are implicated in
the loss of nephron mass that might involve activation of
the renin-angiotensin system (RAS) (5,6).
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In this respect, the pharmacological inhibition of angio-
tensin II synthesis and/or the blockade of its biological
activity remarkably ameliorate the renal interstitial abnor-
malities, reducing the accumulation of protein casts and
ultimately slowing the progression of renal dysfunction in
many renal disease models (7-13). Furthermore, non-
randomized clinical trials have identified the blockade of
RAS as a cardinal means of arresting the progression of
renal disease, delaying the progression of glomeruloscle-
rosis and interstitial fibrosis in proteinuric diseases as well
as CAN (14-21). Some non-randomized clinical studies on
renal transplantation have shown that the blockade of RAS
was safe and beneficial by reducing proteinuria, besides
increasing renal allograft survival (19-21).
Mycophenolate mofetil (MMF) has been used in solid
organ transplants with good results on the reduction of
acute rejection episodes and promoting good graft survival
(22-27). The effect of combined therapy with an angio-
tensin-converting enzyme inhibitor (ACEI) and MMF has
only been analyzed in experimental studies, which showed
a synergistic effect in reducing renal damage (28-30). So
far, no studies have confirmed or denied these findings in
humans. To answer the question of whether ACEI in com-
bination with MMF has the same effect in humans, we
designed this study with patients with biopsy-proven CAN
under ACEI therapy or not, in combination or not with
MMF. Factors associated with a better clinical response
and with improved graft outcomes were investigated. We
anticipated that the use of ACEI would delay the progres-
sion of chronic allograft nephropathy and the use of MMF
would enhance the renoprotective action of ACEI, conse-
quently decreasing renal allograft loss in patients with
CAN.
Subjects and Methods
Subjects
For this retrospective study, a total of 250 consecutive
renal transplant patients with a previous biopsy-proven
CAN were enrolled between 2000 and 2002. The study
was approved by the local Ethics Committee of São Paulo
University. Patients were excluded if: 1) they were the
recipients of a previous organ transplant (N = 9); 2) they
were the recipients of a multiple organ transplant (N = 4); 3)
their biopsy samples could not be recovered for re-analy-
sis (N = 12); 4) the results of biopsy re-analysis did not
meet the minimal Banff criteria for CAN (N = 4); 5) had
recurrence or de novo occurrence of glomerulopathies
post-transplantation (N = 51), or 6) had neoplasias or
polyomavirus infections (N = 9). Thus, 161 transplant
patients with biopsy-proven CAN were evaluated.
Study design
In this retrospective study, after a biopsy-proven diag-
nosis of CAN, the enrolled patients were divided into two
groups defined by the use or not of ACEI therapy for at
least 16 weeks before the diagnosis of CAN. The charac-
teristics of the ACEI therapy group (N = 81, G1) and the
non-ACEI therapy group (N = 80, G2) were then com-
pared. The main clinical indication of ACEI therapy was
hypertension and captopril was the drug used for all G1
patients. The groups were matched for gender, type of
donor (deceased versus living donor), pre-transplant dis-
ease and time of CAN diagnosis and CAN Banff grade.
Stratification according to MMF use
The two groups (G1 and G2) were also subdivided
based on MMF use and the ACEI group (G1) was subdi-
vided into three subgroups: patients who received ACEI
alone (N = 12), patients who received ACEI and MMF
before a biopsy-proven diagnosis of CAN (N = 14), and
patients who received ACEI and MMF after a biopsy-
proven diagnosis of CAN (N = 55). Similarly, patients who
did not use ACEI (G2) were also subdivided into three
subgroups: patients who did not receive ACEI or MMF (N =
19), patients who did not receive ACEI but received MMF
before a biopsy-proven diagnosis of CAN (N = 18), and
patients who did not receive ACEI, but received MMF after
a biopsy-proven diagnosis of CAN (N = 43).
Operational definitions
Delayed graft function was defined as the requirement
of dialysis during the first week after transplantation in the
absence of rejection and/or technical problems. Acute
rejection confirmed by biopsy was defined according to
Banff 97 criteria. Any rejection before the 3rd month of
transplantation was classified as early acute rejection, and
as late rejection after this period. Systemic arterial hyper-
tension was defined as a repeatedly elevated blood pres-
sure exceeding 140 x 90 mmHg or when patients were
using at least one antihypertensive drug. New-onset dia-
betes after transplantation was defined when fasting plas-
ma glucose was ≥126 mg/dL (≥7 mmol/L), when a random
blood sugar level ≥200 mg/dL (≥11.1 mmol/L) accompa-
nied by symptoms was observed, or when an oral glucose
tolerance test showed a value ≥200 mg/dL.
Loss of renal function was considered to be one end-
point in our study. For this purpose, we assessed the
increase in serum creatinine during follow-up. Patients
who had an increase of serum creatinine higher than 30%
compared to baseline level (time of CAN diagnosis) at the
end of follow-up were defined as non-responders. Con-
versely, all patients who did not lose graft function or those
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who showed a less than 30% increase in serum creatinine
over time were defined as responders. Thus, the two
patient groups were subdivided into responders (G1a, N =
71, and G2a, N = 51) and non-responders (G1b, N = 10,
and G2b, N = 29).
Histological analysis
Biopsy specimens were evaluated and graded accord-
ing to the Banff 97 criteria and the histological chronic
allograft damage index (CADI) (31,32). At least four slides
were used to quantitate the histological changes in each
biopsy stained with hematoxylin-eosin, Masson’s trichrome,
periodic acid-Schiff, and silver, respectively. All biopsy
specimens were reviewed by three independent observ-
ers (pathologists) before inclusion of the patient in the
study. The final result regarding the severity of acute and
chronic lesions in each renal compartment was calculated
by applying concordance criteria among these observers.
In the case of discrepancy among the three pathologists,
the mode of the values for each variable was used as the
final grade of lesion severity.
Statistical analyses
Pre-transplant demographic characteristics used for
covariate-adjusted analysis included the type of dialysis
therapy (hemodialysis vs peritoneal dialysis) and the source
of the graft (deceased vs living donor). The age of the
donor (above or below 39 years) and the age of the
recipient (above or below 34 years) were dichotomized.
The cut-off was obtained based on the mean values. The
post-transplant variables included the presence of protein-
uria in 24-h collected samples, delayed graft function,
early and late acute rejection, and cold ischemia time
(above or below 60 min). We examined the proportional-
hazard assumption by plotting the graft survival curves for
each group of a covariate on a log-log scale. Since the
curves appeared to be reasonably parallel, we regarded
the model as appropriate.
A CADI score of 2.3 or higher, a Banff 97 grade higher
than II, a serum creatinine level of 2.5 mg/dL or higher,
creatinine clearance of 60 mL/min, proteinuria of 1 g/24 h
or higher, were considered as cut-off points for statistical
comparison among groups. The cut-off was obtained based
on its best value to predict renal allograft loss. In order to
assess the effect of ACEI therapy alone or in combination
with MMF on erythropoiesis, we determined hematocrit
levels immediately before the use of ACEI and at the end of
follow-up.
The Kaplan-Meier method was used to estimate graft
survival after CAN diagnosis. Graft loss was defined by the
requirement of permanent dialysis after graft failure, and
death of patients with functioning grafts was not consid-
ered as an end-point event. We determined statistical
significance by log-rank comparisons of survival curves
using two-sided P values. Values are reported as means +
SD and, when appropriate, as median and ranges. Para-
metric and non-parametric tests, the chi-square test and
Fisher’s exact test were applied to compare demographic
covariates between groups when appropriate. A P value of
less than 0.05 was considered to be significant.
A multivariate Cox proportional hazards model was
used to analyze the relation between graft loss and other
covariates that were significant in univariate analysis or
were well-known to be involved in graft loss. The Cox
proportional hazard model-enter stepwise procedure was
used to obtain the final model of significant predictors.
Confounding variables were analyzed when required and
were considered to be absent when the exponential coef-
ficient (OR) did not change by more than 10%. The Stata
statistical software 12.0 was used for all statistical analy-
ses (Stata Corporation, USA).
Results
Demographic data of the study population
The demographic characteristics of the population are
reported in Tables 1 and 2. The initial immunosuppression
therapy was cyclosporine for 137 patients (85%), tacroli-
mus for 18 (11%), MMF for 32 (20%), azathioprine for 115
(71%), and sirolimus for 11 (6%). Univariate analysis re-
vealed that dialysis time (P = 0.014), recipient age (P =
0.000), hepatitis (B or C virus-positive serology; P = 0.014),
and post-transplant diabetes mellitus (P = 0.007) were
significantly higher in G1. At the time of ACEI therapy
initiation there were no differences in CAN grade between
the groups or, interestingly, in serum creatinine levels
(Table 2).
ACEI and/or MMF therapy in patients with CAN
Patients with CAN who used ACEI (G1) showed a
marked reduction in proteinuria compared to the group that
did not use ACEI (G2). Furthermore, their serum creatinine
levels stabilized with time (Table 2).
The two groups (G1 and G2) were subdivided into
responders and non-responders on the basis of an in-
crease in baseline serum creatinine of more than 30% at
the end of ACEI therapy. Responder patients on ACEI
therapy not only showed stabilized renal function but also
decreased proteinuria, whereas responder patients on
ACEI-free therapy presented increased proteinuria. Some
patients considered as non-responders in the ACEI thera-
py group showed increased serum creatinine during fol-
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nine and proteinuria were significantly increased only in
the group who never used ACEI or MMF (serum creatinine:
2.0 ± 0.8 vs 2.4 ± 1.6 mg/dL; P = 0.001, proteinuria: 0.4 ±
0.5 vs 1.1 ± 1.2 g/24 h, P < 0.05; Table 2).
In order to assess the effect of ACEI alone or in combi-
nation with MMF on erythropoiesis, we determined the
hematocrit levels immediately before the use of ACEI and
at the end of follow-up. In general, ACEI therapy was
associated with a significant decrease in hematocrit levels.
Patients on ACEI-free therapy, although presenting a re-
duction in hematocrit levels, only showed a statistically
significant difference when also taking MMF.
The association with MMF aggravated ane-
mia (Table 3).
Allograft survival and multivariate
analyses
Figure 1 shows the Kaplan–Meier esti-
mate of graft survival for patients receiving
ACEI therapy (G1) and ACEI-free therapy
(G2). ACEI therapy was associated with
better graft survival after CAN diagnosis.
Multiple ACEI and MMF combinations were
analyzed in a graft survival model. The use
of MMF increased graft survival in patients
who did not use ACEI. In this respect, the
group that did not use ACEI or MMF had a
median 65% censored population, the short-
est survival time among the groups (P =
0.02; Figure 1).
When we analyzed the survival model
using other variables, such as acute rejec-
tion, co-morbidities, CAN grade, CADI score
≥2.3, deceased donor, recipient and donor
ages, cold ischemic time, hemodialysis
therapy, delayed graft function, and anti-
CMV antibodies, we did not observe any
correlations with graft survival rate. The use
of ACEI or MMF therapy was positively as-
sociated with graft survival (Table 4) even
when some of these variables were tested
in multivariate analyses.
Cox regression analyses demonstrated
that the use of ACEI therapy protected 79%
of the patients against graft loss (OR =
0.079, 95%CI = 0.015-0.426; P = 0.003),
showing that ACEI therapy is a protective
factor. The same trend was observed, but to
a lesser extent, for those patients who did
not use ACEI therapy but who were on MMF
therapy after biopsy-proven CAN, and in
low-up, although their proteinuria levels were reduced
(Table 2).
The two groups were further subdivided on the basis of
MMF use as described in Subjects and Methods. In gen-
eral, patients with CAN who used ACEI combined or not
with MMF showed decreased proteinuria. However, we
only observed a statistically significant difference between
patients who used ACEI and MMF after biopsy-proven
CAN and the subgroup that did not use MMF or even those
who were not treated with ACEI (Table 2). In contrast,
among the patients who did not use ACEI, serum creati-
Table 1. Demographic data of the study population.
Variables With ACEI Without ACEI
(G1, N = 81) (G2, N = 80)
Recipient age (years) 37 ± 12 30 ± 12*
Donor age (years) 35 ± 13 39 ± 14
Gender (male) 54% 46%
Deceased donor 38% 37%
HLA matching (living-related donor)
I (identical HLA, O mismatch) 20 2*
II (50% mismatch HLA) 66 76
III (different HLA) 14 22
Hemodialysis therapy 95% 75%
Hemodialysis time (months) 47 ± 41 33 ± 30*
Cold ischemia time (min) 698 ± 1580 564 ± 747
Early acute renal rejection 40% 44%
Later acute renal rejection 11% 19%
Delayed graft function 31% 38%
Diabetes mellitus after transplantation 18% 5%*
Anti-cytomegalovirus antibodies (IgG) 18% 16%
Hepatitis (B or C virus) 28% 20%*
CAN grade at first biopsy
CAN grade 1 50% 63%
CAN grade 2 39% 27%
CAN grade 3 11% 10%
CADI score >2.3 59% 46%
Initial immunosuppressive therapy, N (%)
Cyclosporine 75 (54%) 62 (45%)*
Tacrolimus 2 (11%) 16 (89%)*
Rapamycin 4 (49%) 7 (51%)
Azathioprine 62 (54%) 53 (46%)
MMF 14 (44%) 18 (56%)
Final immunosuppressive therapy, N (%)
Cyclosporine 65 (52%) 61 (48%)
Tacrolimus 4 (22%) 19 (78%)*
Rapamycin 2 (40%) 3 (60%)
Azathioprine 13 (45%) 16 (55%)
MMF 55 (56%) 43 (44%)*
Data are reported as means ± SD or percent. ACEI = angiotensin-converting
enzyme inhibitor; HLA = human leukocyte antigen; CAN = chronic allograft
nephropathy; CADI = chronic allograft damage index; MMF = mycophenolate
mofetil. *P < 0.05 compared with ACEI (Student t-test for independent samples
and chi–square test in categorical variables, both used in normal distribution of
variables).
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Table 2. Renal function (serum creatinine, Scr, mg/dL) and proteinuria levels (Prot, g/24 h) at enrollment (Scr 1 and Prot 1) and at the
end of follow-up (Scr 2 and Prot 2) in patients with or without ACEI therapy (responders = patients who did not lose graft function or
those who showed less than a 30% increase in serum creatinine over time and non-responders), stratified or not for the use of MMF.
Subgroups Scr 1 Scr 2 Prot 1 Prot 2
ACEI therapy (G1) 1.81 ± 0.56 1.87 ± 0.52 1.31 ± 1.94 0.53 ± 0.68*
No use of MMF (N = 12) 1.8 ± 0.7 1.8 ± 0.6 1.2 ± 1.2 0.6 ± 0.7
MMF pre (N = 14) 2.0 ± 0.6 2.0 ± 0.5 0.9 ± 1.6 0.3 ± 0.4
MMF post (N = 55) 1.8 ± 0.5 1.8 ± 0.5 1.4 ± 2.0 0.6 ± 0.7*
ACEI-free therapy (G2) 2.07 ± 0.73 2.65 ± 1.64* 0.51 ± 0.74 0.85 ± 1.01*
No use of MMF (N = 19) 2.0 ± 0.8* 2.4 ± 1.6* 0.4 ± 0.5* 1.1 ± 1.2*
MMF pre (N = 18) 2.1 ± 0.7 2.9 ± 2.1 0.6 ± 1.1 0.8 ± 1.1
MMF post (N = 43) 2.0 ± 0.7 2.4 ± 1.3 0.5 ± 0.7 0.7 ± 0.9
ACEI treatment
Responders 1.84 ± 0.57 1.83 ± 0.51 1.33 ± 2.00 0.52 ± 0.68*
Non-responders 1.52 ± 0.32 2.27 ± 0.52* 1.10 ± 1.12 0.71 ± 0.70
ACEI-free treatment
Responders 1.94 ± 0.54 1.85 ± 0.55 0.38 ± 0.41 0.54 ± 0.56*
Non-responders 2.28 ± 0.40 4.05 ± 1.96* 0.74 ± 1.08 1.40 ± 1.37*
Data are reported as mean ± SD. ACEI = angiotensin converting enzyme inhibitor; MMF = mycophenolate mofetil. *P < 0.05, Scr1 vs
Scr2 and Prot1vs Prot2 (Student t-test).
Figure 1. Graft survival curves for G1 (patient with ACEI) and G2
(patient without ACEI) renal transplanted patients. A, Graft sur-
vival was analyzed after the diagnosis of chronic allograft ne-
phropathy (CAN) in G1 and G2. B, Graft survival was also
analyzed in both groups stratified for the use of mycophenolate
mofetil (MMF) before (pre) or after (post) CAN diagnosis, and
not. All survival curves showed significant differences.
Table 3. Hematocrit values immediately before the introduction
of ACEI and at the end of follow-up in patients with or without
ACEI therapy, stratified or not for the use of MMF.
Subgroups Before After
ACEI therapy (G1)
No use of MMF (N = 12) 39 ± 6.8 34 ± 7.4*
MMF pre (N = 14) 42 ± 6.9 36 ± 4.2*
MMF post (N = 55) 41 ± 7.4 35 ± 4.2*
ACEI-free therapy (G2)
No use of MMF (N = 19) 39 ± 5.8 36 ± 6.1
MMF pre (N = 18) 40 ± 6.4 38 ± 6.5
MMF post (N = 43) 39 ± 7.0 35 ± 6.1*
Data are reported as means ± SD. ACEI = angiotensin-convert-
ing enzyme inhibitor; MMF = mycophenolate mofetil. *P < 0.05
compared to “before” (Student t-test for the same sample).
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Table 4. Univariate analyses of patients with graft loss.
Variables No graft loss Graft loss
(N = 132) (N = 29)
Recipient age (years) 32 ± 13 34 ± 12
Donor age (years) 36 ± 15 37 ± 14
Gender (male) 85 (82%) 14 (18%)
Deceased donor 44 (37%) 12 (41%)
Hemodialysis therapy 123 (93) 29 (100)
Cold ischemic time (min) 660 ± 823 634 ± 1309
Early acute renal rejection 54 (41%) 13 (45%)
Delayed graft function 44 (33%) 11 (38%)
Diabetes mellitus post-transplantation 15 (11%) 4 (14%)
Anti-cytomegalovirus antibodies (IgG) 22 (17%) 6 (21%)
ACEI use 71 (54%) 10 (35%)*
Use of MMF after CAN diagnosis 102 (77%) 17 (58.6%)*
Data are reported as means ± SD or N (%). ACEI = angiotensin-convert-
ing enzyme inhibitor; MMF = mycophenolate mofetil; CAN = chronic
allograft nephropathy. *P < 0.05 compared to no graft loss (Student t-test
for independent samples and chi–square test in categorical variables, both
used in normal distribution of variables).
Table 5. COX-adjusted analysis model for graft loss in the population
studied.
Variables P OR 95%CI
Use of ACEI 0.003 0.079 0.015–0.426
No use of ACEI, but use of MMF post-CAN 0.024 0.108 0.016-0.743
Use of MMF post-CAN 0.001 0.196 0.072-0.529
Donor age (≥39 years) 0.339 1.556 0.628-3.856
Acute rejection 0.360 1.448 0.656-3.194
Delayed graft function 0.451 1.415 0.574-3.488
Recipient age (≥34 years) 0.495 1.340 0.579-3.102
HLA matching (living-related donor) 0.190 1.297 0.879-1.915
Gender (male) 0.571 1.270 0.555-2.909
ACEI = angiotensin-converting enzyme inhibitor; MMF = mycophenolate
mofetil; CAN = chronic allograft nephropathy.
Our results showed that ACEI therapy in pa-
tients with CAN could slow its progression, stabiliz-
ing serum creatinine and decreasing and limiting
the progression of proteinuria as well as histologi-
cal lesions. Patients who received ACEI main-
tained stable renal function with decreasing pro-
teinuria at the end of therapy, in contrast to the
ACEI-free group who presented a progressive loss
of renal function with increasing proteinuria. These
findings correlated with the results of other renal
disease progression studies such as the Ramipril
Efficacy in Nephropathy study of proteinuric non-
diabetic nephropathies (16). ACEI therapy was
associated with increased baseline glomerular fil-
tration rate, possibly indicating a functional regres-
sion of renal disease in some patients.
However, recent data reported by Opelz et al.
(34) demonstrated that no improvement in patient
or graft survival outcome was found in kidney and
heart transplant recipients on ACEI/angiotensin
receptor blocker (ARB) treatment. Another retro-
spective study evaluated the patient and graft sur-
vival rates of 2031 recipients of a first kidney
transplant with or without ACEI and/or ARB thera-
py. Heinze et al. (35) found a marked improvement
in ten-year graft survival in patients on ACEI/ARB
treatment. In these two recent retrospective stud-
ies, the authors did not specifically analyze the
impact on patients with CAN diagnosed by biopsy,
for whom the impact of ACEI/ARB therapy could
be more pronounced.
In this context, an elegant experimental study
from the group of Remuzzi (14) showed that ACEI
therapy could stop proteinuria and glomeruloscle-
rosis, interrupting the progression of chronic al-
lograft dysfunction and injury.
After MMF was introduced in renal transplanta-
tion, some reports have demonstrated its benefit in CAN
(22-24). Ojo et al. (22), in a study on 66,774 human renal
allograft recipients, showed that MMF reduces late al-
lograft loss independently of its effects on acute rejection.
Experimental studies have long evaluated the impact of
MMF in rodent models of end-stage renal disease. In
experimental diabetes involving chronic nitric oxide syn-
thase inhibition in rat models, the use of MMF prevented
the development of glomerular atrophy and the progres-
sion of tubular atrophy and tubulointerstitial fibrosis (36,37).
In the present study, MMF had a synergistic effect with
ACEI since the combination of ACEI and MMF maintained
serum creatinine stable throughout the study and de-
creased proteinuria more than when MMF was used alone.
those who were on ACEI therapy and who initiated MMF
after biopsy-proven CAN (Table 5).
Discussion
The renoprotective effect of ACEI has been estab-
lished in a wide variety of progressive diabetic and non-
diabetic renal diseases (14-21). In renal transplantation,
few clinical studies have shown the beneficial effects of
ACEI therapy (19-21). Interestingly, a reduction in end-
stage renal disease was observed even in clinical cardio-
vascular studies evaluating the benefit of ACEI therapy in
reducing mortality and cardiovascular effects (33).
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The combination of MMF and ACEI was a good prognostic
factor for graft survival even in patients with established
CAN. The death-censored graft survival analysis was much
better for the group treated with ACEI alone, following the
group treated with ACEI in combination with MMF, whereas
the group receiving neither ACEI nor MMF showed the
worst renal allograft outcomes.
The main limitation of our study was the influence of
ACEI and MMF therapy on erythropoiesis. Both therapies
were associated with a decrease in hematocrit levels.
However, this side effect should not limit the use of ACEI in
combination with MMF, with anemia being carefully moni-
tored and the administration of an erythropoietin supple-
ment being considered whenever necessary.
The present study was not randomized and has some
of the limitations of retrospective studies. Many other con-
founding factors could not be eliminated by the statistical
approach used, and should be kept in mind. Randomized
clinical trials would be ideal. However, they involve impor-
tant ethical issues since experimental studies and meta-
analyses of non-transplanted patients have demonstrated
the benefit of both drugs.
Our results indicate that the use of ACEI alone or in
combination with MMF significantly reduces proteinuria
and stabilizes serum creatinine over time, consequently
improving renal allograft survival.
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